US Patent

US8252328 — Bioadhesive drug formulations for oral transmucosal delivery

Formulation · Assigned to AcelRx Pharmaceuticals Inc · Expires 2027-01-05 · 1y remaining

Vulnerability score 60/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects bioadhesive formulations for controlled delivery of oral transmucosal medications, such as sustained release of a medication.

USPTO Abstract

Formulations for controlled delivery of oral transmucosal medications are provided. The formulations are characterized as hydrogel-forming or eroding-types which are bioadhesive and provide for controlled and sustained release of the medication such that enhanced bioavailability and efficacy is provided.

Drugs covered by this patent

Patent Metadata

Patent number
US8252328
Jurisdiction
US
Classification
Formulation
Expires
2027-01-05
Drug substance claim
No
Drug product claim
Yes
Assignee
AcelRx Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.